Application of circRNA (Ribonucleic Acid) as biomarker in panic disorder diagnosis

By detecting the content of circRNA, using circESYT2, circKDM1A and circTMCO4 as biomarkers, the problem of inadequate diagnosis of panic disorder was solved, and a high sensitivity and specific diagnosis was achieved, and the treatment effect was improved.

CN118932047APending Publication Date: 2024-11-12SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411221928.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-02
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The lack of reliable biomarkers in the prior art leads to inadequate diagnosis of panic disorders, low accuracy, and the inability to identify high-risk individuals early, resulting in the failure of patients to receive effective treatment in a timely manner.

Method used

CircRNAs such as circESYT2, circKDM1A and circTMCO4 are used as biomarkers to detect their content, and provide kits and drug treatment screening applications for diagnosis of panic disorders, combined with fluorescence quantitative PCR technology to improve the sensitivity and specificity of the diagnosis.

Benefits of technology

It provides a new, highly sensitive and specific biomarkers that can effectively diagnose panic disorders, improve treatment effects, reduce the burden on patients and society, and has high clinical use value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932047A_ABST
    Figure CN118932047A_ABST
Patent Text Reader

Abstract

The invention discloses application of circRNA (Ribonucleic Acid) as a biomarker in panic disorder diagnosis, and belongs to the field of biomedicine. The invention relates to application of a reagent for detecting circRNA in preparation of a panic disorder diagnosis kit, which is characterized in that the circRNA comprises one or more of circESYT2, circKDM1A and circTMCO4, the circRNA comprises one or more of circESYT2, circKDM1A and circTMCO4, and the circRNA comprises one or more of circESYT2, circKDM1A and circTMCO4. The nucleotide sequence of the circESYT2 is shown as SEQ ID NO. 1, and the nucleotide sequence of the circESYT2 is shown as SEQ ID NO. The nucleotide sequence of the circKDM1A is as shown in SEQ ID NO. 2; the nucleotide sequence of the circTMCO4 is as shown in SEQ ID NO. 3. The technical scheme disclosed by the invention reveals that circESYT2, circKDM1 and circTMCO4 can be used as new detection targets of the panic disorder, a brand new biomarker with high sensitivity and specificity is provided for diagnosis of the panic disorder, and the biomarker has relatively high clinical use and potential value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to the use of circRNA as a biomarker in the diagnosis of panic disorder. Background Art

[0002] Panic disorder (PD) is a common anxiety disorder characterized by sudden intense fear or discomfort, usually accompanied by symptoms such as palpitations, sweating, trembling, and shortness of breath, which seriously affect patients' daily life and social functions. According to statistics, the prevalence of panic disorder worldwide is about 2.7%. PD patients usually have repeated attacks and constantly seek emergency treatment. They may need multiple examinations, resulting in a waste of time and medical resources. Its high prevalence and high recurrence rate make it an important public health issue. Due to the complex etiology and diverse symptoms of panic disorder, clinical diagnosis currently relies mainly on self-reports of patients and observations of doctors, lacking objective biomarkers. This diagnostic method not only relies on subjective judgment and has low accuracy, but also fails to identify high-risk individuals early, resulting in patients failing to receive effective treatment in time. Therefore, it is urgent to find a reliable biomarker to achieve early and objective diagnosis of panic disorder, thereby improving treatment efficacy and reducing the burden on patients and society. Summary of the invention

[0003] In view of the deficiencies of the prior art, the present invention proposes the use of circRNA as a biomarker in the diagnosis of panic disorder.

[0004] The purpose of the present invention can be achieved through the following technical solutions:

[0005] The first aspect of the present invention relates to the use of a reagent for detecting circRNA in the preparation of a diagnostic kit for panic disorder, wherein the circRNA includes one or more of circESYT2, circKDM1A, and circTMCO4;

[0006] The nucleotide sequence of the circESYT2 is shown in SEQ ID NO.1; the nucleotide sequence of the circKDM1A is shown in SEQ ID NO.2; and the nucleotide sequence of the circTMCO4 is shown in SEQ ID NO.3.

[0007] Optionally, the reagent for detecting circ RNA includes reverse transcription primers of circESYT2, circKDM1 and / or circTMCO4.

[0008] Optionally, the reverse transcription primer sequences of circESYT2 are: SEQ ID NO.4; and the reverse primer: SEQ ID NO.5.

[0009] Optionally, the reverse transcription primer sequences of circKDM1 are: forward primer: SEQ ID NO.6; and reverse primer: SEQ ID NO.7.

[0010] Optionally, the reverse transcription primer sequences of circTMCO4 are: SEQ ID NO.8; and the reverse primer: SEQ ID NO.9.

[0011] Optionally, the kit includes relevant reagents for fluorescent quantitative PCR.

[0012] A second aspect of the present invention relates to a kit for diagnosing panic disorder, comprising a reagent capable of detecting the content of circESYT2, a reagent capable of detecting the content of circKDM1A and / or a reagent capable of detecting the content of circTMCO4.

[0013] Optionally, the reagent capable of detecting the content of circESYT2, the reagent capable of detecting the content of circKDM1A, and the reagent capable of detecting the content of circTMCO4 are reverse transcription primers of circESYT2, circKDM1, and circTMCO4, respectively.

[0014] Optionally, related reagents for fluorescence quantitative PCR are also included.

[0015] The third aspect of the present invention relates to the use of a reagent for detecting circRNA in the screening of drugs for the treatment of panic disorder, wherein the circRNA includes one or more of circESYT2, circKDM1A, and circTMCO4;

[0016] The nucleotide sequence of the circESYT2 is shown in SEQ ID NO.1; the nucleotide sequence of the circKDM1A is shown in SEQ ID NO.2; and the nucleotide sequence of the circTMCO4 is shown in SEQ ID NO.3.

[0017] Beneficial effects of the present invention:

[0018] The present invention provides a circRNA marker for diagnosing panic disorder, and based on this, provides a kit for diagnosing panic disorder. The technical solution of the present invention reveals that circESYT2, circKDM1 and circTMCO4 can be used as new detection targets for panic disorder, providing a new, highly sensitive and specific biomarker for the diagnosis of panic disorder, which has high clinical use and potential value. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The present invention will be further described below in conjunction with the accompanying drawings.

[0020] Figure 1 This is a specific implementation flow chart of the present invention for screening and validating panic disorder biomarkers;

[0021] Figure 2 The expression of three circRNAs as biomarkers in plasma samples was screened for big data (copy number / μL);

[0022] Figure 3 This is the correlation analysis between the three screened plasma circRNAs and the scores of panic disorder-related scales;

[0023] Figure 4 Receiver operating characteristic curve analysis (ROC) diagram for the plasma circRNA obtained from patients with panic disorder. DETAILED DESCRIPTION

[0024] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] In the examples of the present application, the circ RNA and its related sequences used are as follows: The nucleotide sequence of circESYT2:

[0026] GTTATTTTCCAGACACTGAAAGAGCAGAATGGCTAAATAAGACTGTAAA

[0027] ACACATGTGGCCTTTCATTTGCCAATTTATAGAGAAGTTGTTTCGAGAAAC

[0028] TATAGAACCAGCCGTGCGGGGAGCAAACACCCACCTTAGCACCTTTAGTTT

[0029] CACGAAGGTCGACGTGGGCCAGCAGCCCCTCAGGATCAATGGTGTTAAGG

[0030] TATACACTGAAAATGTAGACAAAAGGCAAATTATTTTGGACCTTCAGATTA

[0031] GTTTTGTAGGAAATTGTGAGATTGATTTGGAGATCAAACGATATTTTTGTAG

[0032] AGCTGGTGTGAAAAGTATCCAGATTCATGGTACCATGCGGGTGATCCTGGA

[0033] ACCGTTGATTGGAGATATGCCCTTAGTTGGAGCTTTGTCTATCTTCTTCCTT

[0034] AGGAAACCA

[0035] Nucleotide sequence of circKDM1A:

[0036] GTAGAGTACAGAGAGATGGATGAAAGCTTGGCCAACCTCTCAGAAGATGA

[0037] GTATTATTCAGAAGAAGAGAGAAATGCCAAAGCAGAGAAGGAAAAGAAG

[0038] CTTCCCCCACCACCCCCTCAAGCCCCACCTGAGGAAGAAAATGAAAGTGA

[0039] GCCTGAAGAACCATCGGGGCAAGCAGGAGGACTTCAAGACGACAGTTCT

[0040] GGAGGGTATGGAGACGGCCAAGCATCAGGTGTGGAGGGCGCAGCTTTCCA

[0041] GAGCCGACTTCCTCATGACCGGATGACTTCTCAAGAAGCAGCCTGTTTTCC

[0042] AGATATTATCAGTGGACCACAACAGACCCAGAAGGTTTTTCTTTTCATTAG

[0043] AAACCGCACACTGCAGTTGTGGTTGGATAATCCAAAGATTCAGCTGACATT

[0044] TGAGGCTACTCTCCAACAATTAGAAGCACCTTATAACAGTGATACTGTGCT

[0045] TGTCCACCGAGTTCACAGTTATTTAGAGCGTCATGGTCTTATCAACTTCGGC

[0046] ATCTATAAGAGGATAAAACCCCTACCAACTAAAAAGACAGGAAAGGTAATT

[0047] ATTATAGGCTCTGGGGTCTCAGGCTTGGCAGCAGCTCGACAGTTACAAAGT

[0048] TTTGGAATGGATGTCACACTTTTGGAAGCCAGGGATCGTGTGGGTGGACG

[0049] AGTTGCCACATTTCGCAAAGGAAACTATGTAGCTGATCTTGGAGCCATGGT

[0050] GGTAACAGGTCTTGGAGGGAATCCTATGGCTGTGGTCAGCAAACAAGTAA

[0051] ATATGGAACTGGCCAAGATCAAGCAAAAATGCCCACTTTATGAAGCCAAC

[0052] GGACAAGCT

[0053] Nucleotide sequence of circTMCO4:

[0054] AATGGCCGAGGCATCCCGAAAGAAGAAAGAAAACCGGAGGAAATGGAAG

[0055] CGTTATCTCCTGATAGGCCTGGCGACTGTCGGAGGCGGAACGGTGATCGGT

[0056] GTGACTGGAGGTCTAGCTGCACCCCTTGTTGCCGCTGGAGCAGCGACGAT

[0057] TATTGGCAGCGCCGGGGCAGCGGCTCTGGGCTCAGCAGCCGGCATAGCCA

[0058] TCATGACCTCGCTGTTTGGTGCAGCTGGAGCTGGCCTGACAGGATACAAG

[0059] ATGAAGAAGCGAGTGGGAGCCATTGAAGAGTTCACGTTTCTGCCTCTGAC

[0060] GGAGGGCAGGCAGCTGCACATCACCATCGCCGTCACGGGGTGGCTCGCTT

[0061] CTGGCAAATACCGCACCTTCAGTGCCCCGTGGGCTGCCCTGGCCCACAGC

[0062] CGTGAGCAGTACTGCCTGGCCTGGGAAGCCAAGTACCTGATGGAGCTCGG

[0063] CAATGCCCTGGAGACCATCCTCAGTGGTCTCGCCAACATGGTGGCCCAGG

[0064] AGGCCCTAAAGTACACAGTGTTGTCTGGCATTGTGGCTGCCCTGACCTGGC

[0065] CAGCCTCACTCCTCAGTGTCGCCAATGTCATCGACAACCCCTGGGGGGTGT

[0066] GTCTCCATCGATCAGCAGAGGTTGGCAAGCACCTGGCCCACATCCTGCTCT

[0067] CCCGGCAGCAGGGGCGACGACCTGTCACCTTGATTGGCTTCAGCCTGGGA

[0068] GCCAGAGTCATCTACTTCTGTCTGCAGGAGATGGCTCAAGAGAAAG Reverse transcription primer for circESYT2:

[0069] SEQ ID NO.4: 5’-GTACCATGCGGGTGATCCTG-3’

[0070] SEQ ID NO.5: 5’-TGCTAAGGTGGGTGTTTGCT-3’

[0071] Reverse transcription primer for circKDM1

[0072] SEQ ID NO.6: 5’-GGAGGGAATCCTATGGCTGTG-3’

[0073] SEQ ID NO.7:5'-CTTCCTCAGGTGGGGCTTGA-3'

[0074] Reverse transcription primers for circTMCO4:

[0075] SEQ ID NO.8:5'-GACCTGTCACCTTGATTGGC-3

[0076] SEQ ID NO.9:5'-TAGACCTCCAGTCACACCGA-3'

[0077] In some specific examples of the present invention, methods for obtaining and screening biomarkers for panic disorder diagnosis are disclosed, and methods for detecting the content of corresponding markers in plasma samples and their application in panic disorder diagnosis are described. Specifically, Figure 1 As shown in the figure, three patients with panic disorder and three matched healthy volunteers were selected for microarray chip screening of circRNA. Sample preparation and microarray hybridization were performed according to the standard protocol of Arraystar, and the total RNA of each plasma sample was quantified and measured using NanoDrop ND-1000. Total RNA was digested with RNase R to remove linear RNA and enrich circRNA. Then, the enriched circRNA was labeled and hybridized to Arraystar Human circRNA Array V2 using the random primer method. After washing the slides, the array was scanned with Agilent Scanner G2505C. The acquired array images were analyzed using Agilent Feature Extraction software (version 11.0.1.1). The R software limma package was used for quantile normalization and subsequent data processing. The volcano plot was filtered to find the circRNAs that were differentially expressed and statistically significant between the two groups. The t-test was used to estimate the statistical significance of the difference, and circRNAs with Fold Change>2.5 and P value<0.05 were selected as significantly differentially expressed. Finally, hierarchical clustering was performed to show distinct circRNA expression patterns in different samples.

[0078] Three patients with panic disorder were selected as sequencing data sets, and another 61 patients with panic disorder were selected as validation data sets. Finally, three circRNAs were screened out as independent risk factors for panic disorder patients, which can be used as diagnostic markers for panic disorder, namely, one or more of circESYT2, circKDM1A, and circTMCO4. Among them, the nucleotide sequence of circESYT2 is shown in SEQ ID NO.1; the nucleotide sequence of circKDM1A is shown in SEQ ID NO.2; the nucleotide sequence of circTMCO4 is shown in SEQ ID NO.3. Then, the above three circRNAs were used as biomarkers for panic disorder patients and the clinical scoring scale for correlation analysis, and finally the three circRNAs were subjected to ROC curve analysis.

[0079] 61 patients with panic disorder who had not taken any psychotropic drugs within two weeks and 58 healthy control volunteers were collected. Specifically, the diagnosis of panic disorder was diagnosed and confirmed by tertiary psychiatric specialists with rich clinical experience (chief / deputy chief physician, attending physician and senior resident physician) according to the diagnostic criteria for panic disorder in the Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) (DSM-5). The above patients were recruited from the Department of Psychology and Psychiatry of Zhongda Hospital Affiliated to Southeast University, and the healthy controls were from the Physical Examination Center of Zhongda Hospital Affiliated to Southeast University. The plasma samples of the above two groups of subjects were collected and stored in a -80℃ refrigerator. Each plasma sample was centrifuged at 12000g for 15 minutes at room temperature, repeated twice to completely remove cell debris, and the supernatant was collected and stored in a -80℃ refrigerator.

[0080] The tests and evaluations performed included: determination of circRNA copy number in plasma; assessment of the severity of the patient's condition, including the Panic Disorder Severity Scale (PDSS), the Panic-Associate Symptom Scale (PASS), and the Hamilton Anxiety Rating Scale (HAMA).

[0081] Prepare all the necessary items before the test begins. The specific steps are as follows:

[0082] 1. Take out 200-300uL plasma sample, add 5 times volume of TRIZOL reagent, shake vigorously for 15-30s, and let stand at 4℃ for 5 minutes.

[0083] 2. Add 0.2 mL of chloroform to each 1 mL of TRIZOL reagent homogenate. Shake vigorously for 15-30 seconds, let stand at 4°C for 5 minutes, and centrifuge at 12,000 g for 15 minutes at 4°C.

[0084] 3. Transfer the centrifuged aqueous phase to a new EP tube (RNase-free), add 1.5 times the volume of 100% ethanol, and mix thoroughly using a pipette.

[0085] 4. Use a pipette to transfer approximately 700uL of the sample to the RNeasy MinElute spin column in a 2mL collection tube. Close the lid and centrifuge at ≥8000g for 15s at room temperature, and discard the liquid in the collection tube.

[0086] 5. Repeat step 4 for the remaining samples.

[0087] 6. Use a pipette to add 700uL of buffer RWT to the RNeasy MinElute spin column, close the lid, and centrifuge at ≥8000g for 15s at room temperature. Discard the liquid in the collection tube.

[0088] 7. Add 500uL of Buffer RPE to the RNeasy MinElute spin column, close the lid, and centrifuge at ≥8000g for 15s at room temperature. Discard the liquid in the collection tube.

[0089] 8. Add 500uL of 80% ethanol to the RNeasy MinElute spin column, close the lid, and centrifuge at ≥8000g for 2 minutes at room temperature, discarding the liquid in the collection tube.

[0090] 9. Place the RNeasy MinElute spin column in a new 2 mL collection tube (RNase-free). Open the spin column cap, centrifuge at full speed for 5 minutes to dry the membrane, and discard the collection tube.

[0091] 10. Place the RNeasy MinElute spin column in a new 1.5 mL RNase-free EP tube and add 14 uL of RNase-free water to the center of the spin column membrane. Gently close the spin column cap and centrifuge at full speed for 1 minute to elute the RNA.

[0092] 11. Quantitatively measure the concentration and purity of total RNA of each sample using NanoDrop1000.

[0093] 12. cDNA synthesis:

[0094] (1) Prepare the reaction solution: Place 4× gDNA wiper Mix, 5× qRT Super Mix II, total RNA template, and DEPC water on ice, shake and mix thoroughly, and centrifuge after dissolving.

[0095] (2) Prepare the reaction solution: Prepare the reaction solution as shown in Table 1.

[0096] Table 1. Reaction solution composition

[0097]

[0098] (3) Reverse transcription reaction and reverse inactivation: 4× gDNA wiper Mix, total RNA template and DEPC-treated water were added, and the reaction solution was incubated at 42°C for 2 minutes. Then, 5× qRT Super Mix II was added and incubated at 50°C for 15 minutes and 85°C for 2 minutes to inactivate the reverse transcriptase.

[0099] 13. Real-Time PCR Amplification:

[0100] (1) Prepare reagents: cDNA template, 2×AceQ qPCR SYBR Green Master Mix, DEPC water, and circRNA upstream and downstream primers.

[0101] (2) Instrument: QuantStudio TM 5System(272531287).

[0102] (3) Prepare the reaction solution: Prepare the reaction solution as shown in Table 2.

[0103] Table 2 Reaction solution composition

[0104]

[0105] (4) Real-Time PCR amplification: Real-Time PCR amplification was performed according to the reaction conditions in Table 3.

[0106] Table 3. Reaction conditions

[0107]

[0108] 14. Data analysis method: The ΔCt method was used to record the Ct value of the sample, and the absolute copy number of the measured sample was calculated based on the synthesized circRNA standard curve. The absolute qPCR technology was used to estimate the copy number of circESYT2, circKDM1 and circTMCO4 in plasma samples. The standard curve was drawn by 10-fold dilution of plasmids with different concentrations using fluorescent quantitative PCR technology. The copy number of the standard compound was calculated according to the following formula: Copy number (copy / μL) = 6.02×10 23 ×Plasmid concentration (ng / μL)×10 -9 / [(vector molecular weight + insert molecular weight) × 660] (g / mol). The equations of the amplification curve and the standard curve are: Y = aX + b, where the logarithm of the initial amplification copy number is the horizontal axis (X) and the corresponding cycle number is the vertical axis (Y). Using the linear equation of the plasmid standard, the Ct value of the circRNA is converted into arbitrary units to calculate the copy number of the circRNA. The experimental verification results showed that the expression of these three circRNAs in patients with panic disorder was significantly higher than that in healthy controls (see Figure 2 ).

[0109] 15. Correlation analysis of clinical scale scores

[0110] The demographic and clinical characteristics of the subjects are shown in Table 4. According to the clinical rating scale of patients with panic disorder, correlation analysis showed that circESYT2 was positively correlated with PDSS score (r = 0.269, P = 0.042) and PASS score (r = 0.293, P = 0.026) ( Figure 3 A). circKDM1 was positively correlated with PDSS score (r=0.263, P=0.046) and negatively correlated with somatic anxiety score (r=-0.375, P=0.004) ( Figure 3 B). These results suggest that circESYT2 and circKDM1 have good clinical relevance to panic disorder.

[0111] 16. ROC diagnostic prediction analysis

[0112] ROC curve analysis was used to evaluate the predictive diagnostic value of the three circRNAs for patients with panic disorder. The area under the ROC curve of circESYT2 plasma samples was 0.817 ( Figure 4 A), the area under the ROC curve of circKDM1 plasma samples was 0.745 ( Figure 4 B), the area under the ROC curve of circTMCO4 plasma samples was 0.643 ( Figure 4 C), the combined ROC curve area of ​​the above three circRNAs was 0.852 ( Figure 4 D), indicating good discrimination ability between patients with panic disorder and healthy controls.

[0113] In the technical solution of the present invention, the combination of the three markers circESYT2, circKDM1 and circTMCO4 can preliminarily achieve the effect of diagnosis. However, those skilled in the art should know that in the actual process of performing the diagnosis, it is not limited to using these three circRNAs as the only diagnostic indicators, and other well-known diagnostic indicators and well-known symptoms can also be combined to obtain a more accurate diagnostic effect. In other words, the above embodiments of the present invention do not imply that these three circRNAs can only be used as separate indicators for diagnosis. In addition, the above-mentioned well-known diagnostic indicators and symptoms can be queried according to well-known technical information, and this application will not repeat them.

[0114] Table 4General demographic data and clinical characteristics between PDand HC.

[0115]

[0116] In the description of this specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0117] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention may have various changes and improvements, and these changes and improvements all fall within the scope of the present invention to be protected.

Claims

1. Use of a reagent for detecting circRNA in preparing a panic disorder diagnostic kit, characterized in that: The circRNA includes one or more of circESYT2, circKDM1A, and circTMCO4; The nucleotide sequence of the circESYT2 is shown in SEQ ID NO.1; the nucleotide sequence of the circKDM1A is shown in SEQ ID NO.2; and the nucleotide sequence of the circTMCO4 is shown in SEQ ID NO.

3.

2. Use of the reagent for detecting circRNA according to claim 1 in preparing a diagnostic kit for panic disorder, characterized in that: The reagents for detecting circRNA include reverse transcription primers of circESYT2, circKDM1 and / or circTMCO4.

3. Use of the reagent for detecting circRNA according to claim 2 in preparing a diagnostic kit for panic disorder, characterized in that: The reverse transcription primer sequences of circESYT2 are: forward primer: SEQ ID NO.4; and reverse primer: SEQ ID NO.

5.

4. Use of the reagent for detecting circRNA according to claim 2 in preparing a diagnostic kit for panic disorder, characterized in that: The reverse transcription primer sequences of circKDM1 are: forward primer: SEQ ID NO.6; and reverse primer: SEQ ID NO.

7.

5. Use of the reagent for detecting circRNA according to claim 2 in preparing a diagnostic kit for panic disorder, characterized in that: The reverse transcription primer sequences of circTMCO4 are: forward primer: SEQ ID NO.8; and reverse primer: SEQ ID NO.

9.

6. Use of the reagent for detecting circRNA according to claim 1 in preparing a diagnostic kit for panic disorder, characterized in that: The kit includes relevant reagents for fluorescence quantitative PCR.

7. A kit for diagnosing panic disorder, comprising a reagent capable of detecting the content of circESYT2, a reagent capable of detecting the content of circKDM1A and / or a reagent capable of detecting the content of circTMCO4.

8. The kit for diagnosing panic disorder according to claim 7, characterized in that: The reagent capable of detecting the content of circESYT2, the reagent capable of detecting the content of circKDM1A, and the reagent capable of detecting the content of circTMCO4 are respectively the reverse transcription primers of circESYT2, circKDM1, and circTMCO4.

9. The kit for diagnosing panic disorder according to claim 7, characterized in that: Also included are related reagents for fluorescent quantitative PCR.

10. Use of a reagent for detecting circRNA in screening for drugs for the treatment of panic disorder, characterized in that: The circRNA includes one or more of circESYT2, circKDM1A, and circTMCO4; The nucleotide sequence of the circESYT2 is shown in SEQ ID NO.1; the nucleotide sequence of the circKDM1A is shown in SEQ ID NO.2; and the nucleotide sequence of the circTMCO4 is shown in SEQ ID NO.3.